Semaglutide 5mg

Quickstart Highlights

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with a prolonged half-life of approximately 7 days[1], approved for chronic weight management and glycemic control. The extended half-life enables once-weekly subcutaneous dosing, which is the standard clinical approach[1]. This educational protocol presents a gradual weekly titration from 0.25 mg up to a maintenance dose of 2.4 mg over 16+ weeks, using a practical dilution for precise insulin-syringe measurements.

Reconstitute: Add 2.0 mL bacteriostatic water → ~2.5 mg/mL concentration.
Weekly dose range: 250–2400 mcg (0.25–2.4 mg) once weekly (gradual escalation protocol).
Easy measuring: At 2.5 mg/mL, 1 unit = 0.01 mL ≈ 25 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 28 days.

Dosing & Reconstitution Guide

Educational guide for reconstitution and weekly dosing

Standard / Gradual Titration (2 mL = ~2.5 mg/mL)

Week	Weekly Dose	Units (per injection) (mL)
Weeks 1–4	250 mcg (0.25 mg)	10 units (0.10 mL)
Weeks 5–8	500 mcg (0.5 mg)	20 units (0.20 mL)
Weeks 9–12	1000 mcg (1.0 mg)	40 units (0.40 mL)
Weeks 13–16	1700 mcg (1.7 mg)	68 units (0.68 mL)
Weeks 17+ (Maintenance)	2400 mcg (2.4 mg)	96 units (0.96 mL)

Frequency: Inject once weekly subcutaneously. This gradual titration protocol improves tolerability and is consistent with FDA-approved dosing strategies for weight management[1][3]. Administer on the same day each week at any time, with or without meals. Note: We use 2.0 mL reconstitution (instead of 3.0 mL) to keep the highest maintenance dose under 1.0 mL per injection.

Reconstitution Steps

Reference-derived details for Semaglutide 5mg.

Draw 2.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall to minimize foaming; avoid shaking.
Gently swirl or roll the vial until the powder is fully dissolved.
Label the vial with the reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Use reconstituted solution within 28 days for maximum potency and safety[8]. Open source

Supplies Needed

Plan based on an 8–20 week weekly titration protocol.

Peptide Vials (Semaglutide, 5 mg each):
Peptide Vials (Semaglutide, 5 mg each):: 8 weeks ≈ 1 vial (3 mg total used)
Peptide Vials (Semaglutide, 5 mg each):: 12 weeks ≈ 2 vials (7 mg total used)
Peptide Vials (Semaglutide, 5 mg each):: 16 weeks ≈ 3 vials (13.8 mg total used)
Peptide Vials (Semaglutide, 5 mg each):: 20 weeks ≈ 5 vials (23.4 mg total used with maintenance dosing)
Insulin Syringes (U-100):
Insulin Syringes (U-100):: Per week: 1 syringe
Insulin Syringes (U-100):: 8 weeks: 8 syringes
Insulin Syringes (U-100):: 12 weeks: 12 syringes
Insulin Syringes (U-100):: 16 weeks: 16 syringes
Insulin Syringes (U-100):: 20 weeks: 20 syringes
Bacteriostatic Water (10 mL bottles): Use ~2.0 mL per vial for reconstitution.Note: Use bacteriostatic water within 28 days after opening[9]. Open source
Bacteriostatic Water (10 mL bottles): Use ~2.0 mL per vial for reconstitution.Note: Use bacteriostatic water within 28 days after opening[9]. - 8 weeks (1 vial): 2 mL → 1 × 10 mL bottle Open source
Bacteriostatic Water (10 mL bottles): Use ~2.0 mL per vial for reconstitution.Note: Use bacteriostatic water within 28 days after opening[9]. - 12 weeks (2 vials): 4 mL → 1 × 10 mL bottle Open source
Bacteriostatic Water (10 mL bottles): Use ~2.0 mL per vial for reconstitution.Note: Use bacteriostatic water within 28 days after opening[9]. - 16 weeks (3 vials): 6 mL → 1 × 10 mL bottle Open source
Bacteriostatic Water (10 mL bottles): Use ~2.0 mL per vial for reconstitution.Note: Use bacteriostatic water within 28 days after opening[9]. - 20 weeks (5 vials): 10 mL → 1 × 10 mL bottle Open source
Alcohol Swabs: One for the vial stopper + one for the injection site each week.
Alcohol Swabs: One for the vial stopper + one for the injection site each week.: Per week: 2 swabs
Alcohol Swabs: One for the vial stopper + one for the injection site each week.: 8 weeks: 16 swabs
Alcohol Swabs: One for the vial stopper + one for the injection site each week.: 12 weeks: 24 swabs
Alcohol Swabs: One for the vial stopper + one for the injection site each week.: 16 weeks: 32 swabs
Alcohol Swabs: One for the vial stopper + one for the injection site each week.: 20 weeks: 40 swabs → recommend 1 × 100-count box

Protocol Overview

Concise summary of the once-weekly regimen.

Goal: Support chronic weight management through GLP-1 receptor activation, leading to reduced appetite and improved metabolic parameters[1]. Open source
Schedule: Weekly subcutaneous injections for 16–20+ weeks with gradual dose escalation.
Dose Range: 250 mcg (0.25 mg) to 2400 mcg (2.4 mg) weekly with stepwise titration every 4 weeks to improve tolerability.
Reconstitution: 2.0 mL per 5 mg vial (~2.5 mg/mL) for accurate unit measurements on standard insulin syringes.
Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 28 days; avoid repeated freeze–thaw cycles.

Dosing Protocol

Suggested weekly titration approach based on clinical approval and studies[1][3].

Weeks 1–4: 250 mcg (0.25 mg) once weekly to establish baseline tolerance.
Weeks 5–8: 500 mcg (0.5 mg) once weekly.
Weeks 9–12: 1000 mcg (1.0 mg) once weekly.
Weeks 13–16: 1700 mcg (1.7 mg) once weekly.
Weeks 17+ (Maintenance): 2400 mcg (2.4 mg) once weekly as target maintenance dose.
Frequency: Once per week (subcutaneous injection).
Timing: Administer on the same day each week at any time; rotate injection sites to reduce local irritation.

Storage Instructions

Proper storage preserves peptide quality and efficacy[7][8].

Lyophilized (powder): Store at −20 °C (−4 °F) in a cool, dry place protected from light. For short-term storage (under a few months), 2–8 °C (35.6–46.4 °F) refrigeration is acceptable[7]. Avoid humidity to prevent peptide degradation. Open source
Reconstituted (solution): Refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze[8]. Use within 28 days for maximum potency and safety; the benzyl alcohol in bacteriostatic water inhibits bacterial growth but solutions should still be discarded after approximately 4 weeks[9]. Open source
Allow vials to reach room temperature before opening to minimize condensation uptake.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each injection; dispose in a proper sharps container[11]. Open source
Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and avoid lipohypertrophy[10]. Open source
Inject slowly and steadily; wait a few seconds before withdrawing the needle to ensure complete delivery.
Administer on the same day each week for consistency; if a dose is missed, take it as soon as possible within 5 days of the missed dose[4]. Open source
GLP-1 receptor agonists may cause gastrointestinal side effects (nausea, vomiting); gradual dose escalation helps minimize these effects[1][3]. Open source
The 5 mg vial size offers flexible dosing options—plan for 1 vial per 8 weeks during the initial escalation phase.

How This Works

Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to native human GLP-1[4]. It promotes weight loss through multiple mechanisms: reducing appetite and food intake via central nervous system effects, slowing gastric emptying, and improving glycemic control through glucose-dependent insulin secretion[1][3]. The extended half-life of approximately 7 days is due to albumin binding and resistance to DPP-4 degradation, enabling convenient once-weekly dosing[1]. Clinical trials have demonstrated significant weight loss (mean 10–15% body weight reduction) in individuals with obesity when combined with lifestyle interventions[1][5]. The weekly 2.4 mg maintenance dose is FDA-approved for chronic weight management and represents the standard clinical approach[3][4].

Lifestyle Factors

Complementary strategies for optimal outcomes with GLP-1 therapy[1][5].

Maintain a balanced, calorie-controlled diet with adequate protein intake (1.2–1.6 g/kg body weight) to preserve lean muscle mass during weight loss.
Combine regular physical activity including both resistance training (2–3 days per week) and aerobic exercise (150+ minutes per week) to reinforce metabolic adaptations and improve body composition.
Prioritize consistent sleep (7–9 hours nightly) and effective stress management to support adherence and metabolic health.
Stay well-hydrated (8–10 glasses of water daily), especially if experiencing gastrointestinal side effects.
Monitor progress through regular weigh-ins, body measurements, photos, and consultation with healthcare providers.
Consider working with a registered dietitian for personalized nutrition guidance during weight loss.

Potential Benefits & Side Effects

Observations from clinical literature and regulatory approvals[1][3][5].

Significant weight loss (mean 10–15% body weight reduction in clinical trials at 2.4 mg weekly dose) when combined with lifestyle modifications[1][5]. Open source
Improved glycemic control through enhanced glucose-dependent insulin secretion and reduced glucagon secretion[3]. Open source
Reduced appetite and food intake via central nervous system GLP-1 receptor activation[1]. Open source
Cardiovascular benefits demonstrated in outcome trials, including reduced risk of major adverse cardiovascular events[6]. Open source
Convenient once-weekly dosing improves adherence compared to daily regimens[1]. Open source
Gastrointestinal effects (most common): nausea, vomiting, diarrhea, constipation, abdominal pain—typically mild to moderate and decreasing with gradual dose escalation[1][3]. Open source
Injection-site reactions: redness, swelling, or irritation (generally mild and transient)[11]. Open source
Hypoglycemia risk (when combined with insulin or sulfonylureas)—less common with semaglutide monotherapy due to glucose-dependent mechanism[3]. Open source
Rare serious adverse events: pancreatitis, gallbladder disease, acute kidney injury; thyroid C-cell tumors observed in rodent studies (relevance to humans uncertain)[4]. Open source

Injection Technique

General subcutaneous injection guidance from clinical best-practice resources[10][11][12].

Clean the vial stopper and chosen skin site with separate alcohol swabs; allow both to dry completely before proceeding[11]. Open source
Pinch a fold of skin between your fingers; insert the needle at a 45–90° angle into the subcutaneous tissue (fatty layer, not muscle)[10][12]. Open source
Do not aspirate (pull back the plunger) when giving a subcutaneous injection[10]. Open source
Inject the solution slowly and steadily; wait at least 6 seconds after injection before withdrawing the needle to ensure complete delivery and minimize leakage.
Withdraw the needle and apply light pressure with a clean swab; avoid rubbing vigorously.
Rotate injection sites systematically (abdomen, thighs, upper arms) with each weekly injection to prevent lipohypertrophy and maintain consistent absorption[11]. The abdomen is the preferred site for most consistent absorption. Open source
Dispose of used syringes and needles immediately in a proper FDA-approved sharps container[12]. Open source

Recommended Source

We recommend Pure Lab Peptides for high-purity Semaglutide (5 mg).

High-purity, third-party-tested peptides with batch-specific Certificates of Analysis (COAs).
Consistent, ISO-aligned handling and quality documentation.
Reliable fulfillment with cold-chain integrity to preserve peptide stability.
Transparent testing and verification processes for research-grade peptides.
Flexible vial size—ideal for users titrating through different dose levels with predictable vial consumption.
Shop at Pure Lab Peptides

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

References